ReviewMolecular and cellular biochemistry2025
Deciphering the enigma: long noncoding RNAs in disease pathogenesis and therapeutic prospects.
Review in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rethinking PDAC: from immunological silence to therapeutic opportunity.Frontiers in immunology · 2026Review
- LncRNA Knockdown Using Gapmer Antisense Oligonucleotides.Methods in molecular biology (Clifton, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advancements in disease understanding and therapeutic interventions, the global burden of diseases continues to increase rapidly, emphasizing the need for novel insights and approaches. Long noncoding RNAs (lncRNAs) have emerged as key players in biological processes and influence gene expression regulation and cellular signalling pathways. This review explores the complex roles of lncRNAs in modulating chromatin function, regulating nuclear bodies, and impacting posttranslational modifications. Moreover, their interactions with various RNA species and proteins significantly influence cell signalling cascades, thereby contributing to diverse pathophysiological conditions, including cancer, neurological disorders, metabolic syndromes, and autoimmune diseases. We highlight the potential of lncRNAs as diagnostic biomarkers and therapeutic targets in clinical settings. By describing the complex involvement of lncRNAs in disease mechanisms, this review aims to stimulate further research in this field, encouraging a deeper understanding of disease pathogenesis and paving the way for innovative therapeutic strategies.
Indexed as
Identifiers
40810918What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.